Double-blind assessment of potential pergolide-induced cardiotoxicity.
Possible pergolide-induced cardiotoxicity has been reported in open trials. Over a 6-month period of observation, we prospectively analyzed ECGs and 24-hour ambulatory ECG in 23 patients with Parkinson's disease who were randomized in a double-blind fashion to pergolide or placebo treatments. Pergolide therapy was associated with a mild and transient bradycardiac effect, but no clinically significant cardiotoxicity.
D000368:Aged; D001919:Bradycardia / Q000139:chemically induced; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004562:Electrocardiography; D004873:Ergolines / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006321:Heart / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D010300:Parkinson Disease / Q000188:drug therapy*; D010479:Pergolide; D011446:Prospective Studies
D004873:Ergolines; D010479:Pergolide